Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

[11] Cover TL(1995). MALT lymphoma study group Aliment Pharmacol Ther 9 59-69

[12] Blaser MJ(2005)Outcomes research in Gastroenterology 128 1838-1844

[13] Go MF(2004) infection Am J Gastroenterol 99 1833-1855

[14] Bayerdorffer E(1999)The role of economic evaluation in the diagnosis and treatment of Pharmacoeconomics 16 297-306

[15] Neubauer A(1999) infection J Gastroenterol Hepatol 14 977-983

[16] Rudolph B(2003): the etiologic agent for peptic ulcer Can J Gastroenterol 17 30B-32B

[17] Fendrick AM(2005)The prevalence of Fundam Clin Pharmacol 19 421-427

[18] Fendrick AM(1995) in peptic ulcer disease Arch Intern Med 155 1958-1964

[19] Marshall BJ(1998) “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis BMJ 316 1648-1654

[20] Kuipers EJ(2005)Eradication therapy in Helicobacter 10 22-32

[11] Cover TL(1995). MALT lymphoma study group Aliment Pharmacol Ther 9 59-69

[12] Blaser MJ(2005)Outcomes research in Gastroenterology 128 1838-1844

[13] Go MF(2004) infection Am J Gastroenterol 99 1833-1855

[14] Bayerdorffer E(1999)The role of economic evaluation in the diagnosis and treatment of Pharmacoeconomics 16 297-306

[15] Neubauer A(1999) infection J Gastroenterol Hepatol 14 977-983

[16] Rudolph B(2003): the etiologic agent for peptic ulcer Can J Gastroenterol 17 30B-32B

[17] Fendrick AM(2005)The prevalence of Fundam Clin Pharmacol 19 421-427

[18] Fendrick AM(1995) in peptic ulcer disease Arch Intern Med 155 1958-1964

[19] Marshall BJ(1998) “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis BMJ 316 1648-1654

[20] Kuipers EJ(2005)Eradication therapy in Helicobacter 10 22-32